Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

McGill Transtympanic Ringer's Lactate Cisplatin Otoprotection Study

Also known as: Ringer's Lactate (0.03% Ciprofloxacin), Transtympanic Ringer's Lactate, Transtympanic Administration of Lactate, NCT01108601

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 1/2

Status

Unknown

Target Gene

—

Route / Mode

Transtympanic ear drops via pressure-equalizing tube

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

Canada

Population

adult, cisplatin-ototoxicity

Trial IDs

Mechanism

Phase 1/2 institution-led study of transtympanic Ringer's lactate solution, with 0.03% ciprofloxacin, as otoprotection during cisplatin or carboplatin chemotherapy.

Indications

Hearing Loss Cisplatin-Induced Hearing Loss

Notes

Verified as an old institution-led otoprotection study. Registry status is Unknown and no current commercial Ringer's lactate otoprotection program was established in this pass.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT01108601

Open

Key Events

2008-04-01

Registry lists study start for transtympanic Ringer's lactate cisplatin otoprotection trial

Clinical Trials (1)

NCT01108601

Data Checks